Arcede Pharma, Iconovo and Lund University has received just over SEK 2 million from Swelife for the development of the inhaled treatment RCD405 for COPD and severe asthma. The grant will be used to develop an inhalation product for use in clinical studies and continue to study the candidate's dual mechanism of action.